Abstract：
:The 26S proteasome is an adenosine triphosphate-dependent multicatalytic protease that is responsible for most nonlysosomal intracellular protein degradation. To be selected for proteasomal degradation, proteins must be previously tagged with a polyubiquitin chain, which is then recognized by the proteasome; the ubiquitin chain is removed by isopeptidases and the protein is hydrolysed to small polypeptides. In addition to removing damaged/unnecessary proteins, the proteasome is also an important mechanism of regulation of some key regulatory proteins and their inhibitors. This regulation is crucial for the control of many cellular processes, including activation of transcription factors, cell cycle progression, and apoptosis. The critical role of the ubiquitin-proteasome pathway in tumor cells has led to the investigation of proteasome inhibition as a potential anticancer therapy. The dipeptide boronic acid analogue bortezomib, formerly known as PS-341, is a potent, highly selective, and reversible proteasome inhibitor. The first drug of this class to be used in the clinical setting, it has recently been approved by the US Food and Drug Administration for the treatment of relapsed and refractory multiple myeloma and is currently being tested in clinical trials for the treatment of a wide variety of malignancies. This article provides a summary of the biology of the ubiquitin-proteasome pathway, reviews the available preclinical and clinical data of proteasome inhibition as a therapeutic strategy in breast cancer, and discusses future combination regimens involving bortezomib.
journal_name
Clin Breast Cancerjournal_title
Clinical breast cancerauthors
Cardoso F,Ross JS,Picart MJ,Sotiriou C,Durbecq Vdoi
10.3816/cbc.2004.n.020keywords:
subject
Has Abstractpub_date
2004-06-01 00:00:00pages
148-57issue
2eissn
1526-8209issn
1938-0666pii
S1526-8209(11)70362-7journal_volume
5pub_type
杂志文章,评审abstract：BACKGROUND:Two large randomized trials, CALGB 9343 and PRIME II, support omission of radiotherapy after breast conserving surgery (BCS) in elderly women with favorable-risk early stage breast cancer intending to take endocrine therapy. However, patients with grade 3 histology were underrepresented on these trials. We h...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2020.05.007
更新日期：2020-12-01 00:00:00
abstract：BACKGROUND:Seromas constitute a common complication following surgery for breast cancer, and closed drainage is used routinely to reduce its incidence. The aim of this study was to evaluate the influence of number of drains on patient discomfort, seroma formation, and hospital stay during the immediate postoperative pe...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.3816/CBC.2009.n.041
更新日期：2009-11-01 00:00:00
abstract：:Intravenous bisphosphonates are the preferred treatment to prevent skeletal complications for patients with breast cancer and bone metastases. Pamidronate, a single-nitrogen bisphosphonate, was the early standard of care for such patients based on 2 large, placebo-controlled trials involving 754 patients. Zoledronic a...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.3816/CBC.2005.n.014
更新日期：2005-06-01 00:00:00
abstract：:Fulvestrant, an estrogen receptor antagonist that downregulates the estrogen receptor but has no known agonist effects, has been evaluated in 2 randomized trials involving postmenopausal women with hormone receptor-positive, progressive advanced-stage breast cancer after disease progression with antiestrogen therapy. ...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.3816/cbc.2005.s.009
更新日期：2005-04-01 00:00:00
abstract：:This article discusses the rationale for 2 methods of making estimates of the benefit of letrozole as extended adjuvant hormonal therapy after 5 years of tamoxifen. It uses information from the Overview metaanalyses to develop general rules for making estimates of remaining risk of relapse for women completing 5 years...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.3816/cbc.2004.n.047
更新日期：2004-10-01 00:00:00
abstract：BACKGROUND:Triple-negative breast cancer (TNBC) is an aggressive disease without established targeted treatment options for patients with metastatic disease. This study was undertaken to evaluate potentially actionable biomarkers in a large cohort of TNBC and compare them with non-TNBCs. MATERIALS AND METHODS:We evalu...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2015.04.008
更新日期：2015-12-01 00:00:00
abstract：BACKGROUND:Triple-negative breast carcinoma is defined by a primary tumor that is estrogen receptor negative, progesterone receptor negative, and HER2 negative. The current study was performed to determine the relationship of triple-negative tumor status to outcome after breast conservation treatment with radiation. P...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.3816/CBC.2009.n.018
更新日期：2009-05-01 00:00:00
abstract：INTRODUCTION:The purpose of the study was to determine predictors of recurrence for patients treated with neoadjuvant chemotherapy (NAC) and mastectomy according to the use of postmastectomy radiation therapy (PMRT). PATIENTS AND METHODS:An analysis of 161 clinically staged T1 to T3/N0 to N3 patients treated with NAC ...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2014.09.012
更新日期：2015-04-01 00:00:00
abstract：:The potential for cardiac toxicity in association with targeted biologic agents was first observed with trastuzumab, a monoclonal antibody that targets the ErbB2/HER2 receptor. In the pivotal trial of trastuzumab in ErbB2-positive metastatic cancer, an increased incidence of serious cardiac events was observed, partic...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.3816/cbc.2008.s.007
更新日期：2008-03-01 00:00:00
abstract：BACKGROUND:Recent observational studies are concerning because they document rising mastectomy rates coinciding with more than a dozen reports that lumpectomy has better overall survival (OS) than mastectomy. Our aim was to determine if there were differences in OS of matched breast cancer patients undergoing lumpectom...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2019.02.006
更新日期：2019-06-01 00:00:00
abstract：BACKGROUND:Eribulin has efficacy in patients with progression after ≥ 1 chemotherapeutic regimen for metastatic breast cancer (MBC). A short disease-free interval (DFI) and previous use of taxanes in the neoadjuvant or adjuvant setting have been associated with worse outcomes for patients receiving first-line chemother...
journal_title：Clinical breast cancer
pub_type： 杂志文章,多中心研究
doi：10.1016/j.clbc.2018.12.012
更新日期：2019-04-01 00:00:00
abstract：INTRODUCTION:The adjuvant trastuzumab trials largely excluded women with small, node-negative, HER2-positive breast cancers. Accordingly, limited data exist regarding the effect of trastuzumab in the management of these patients. Our aim was to assess the outcomes of, and treatments administered to, women with small (≤...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2014.12.012
更新日期：2015-08-01 00:00:00
abstract：:The elderly population has been neglected by the traditional approach to clinical breast cancer research. Elderly women have been underrepresented in breast cancer clinical trials, with the majority of studies being restricted to patients aged < 70 years. Elderly patients frequently have comorbidities and/or impaired ...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.3816/cbc.2004.n.022
更新日期：2004-08-01 00:00:00
abstract：BACKGROUND:The inexpensive prediction of the characteristics of BRCA-mutated breast cancer as "BRCAness" using the somatic cells of patients with breast cancer could be useful for developing a therapeutic strategy. Our objective was to correlate BRCAness with the clinicopathologic features, including a family history (...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2018.05.008
更新日期：2018-10-01 00:00:00
abstract：BACKGROUND:The objective of the study was to compare the accuracy of different magnetic resonance (MR) sequences for measuring tumor size and to evaluate whether the imaging and histopathologic features affect the accuracy of the tumor size estimation on the MR sequence. PATIENTS AND METHODS:Eight hundred women were i...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2016.07.007
更新日期：2016-12-01 00:00:00
abstract：PURPOSE:In order to evaluate the feasibility of dose-dense docetaxel followed by dose-dense AC (doxorubicin/cyclophosphamide) as adjuvant chemotherapy for operable breast cancer, we conducted a phase II study. PATIENTS AND METHODS:In cohort 1, 28 patients received docetaxel 100 mg/m2 followed by doxorubicin 60 mg/m2 w...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.3816/CBC.2007.n.029
更新日期：2007-08-01 00:00:00
abstract：BACKGROUND:The American Joint Committee on Cancer (AJCC) staging system is the reference standard for describing the extent of neoplastic disease on the basis of the size of primary tumor (T), and the presence of regional lymph node (N) involvement and distant metastasis (M). Multiple foci of invasive breast carcinoma ...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2020.11.018
更新日期：2020-12-05 00:00:00
abstract：INTRODUCTION:Ensuring guideline-concordant cancer care is a Department of Veterans Affairs (VA) priority, especially as the number of breast cancer patients at VA medical centers (VAMCs) grows. We assessed the utilization and clinical impact of the 21-gene Recurrence Score test, which predicts 10-year risk of breast ca...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2017.11.018
更新日期：2018-04-01 00:00:00
abstract：:Adherence to endocrine therapy (ET) is a longstanding problem in breast cancer (BC) survivorship care, particularly among younger women. Younger patients have reported lower ET initiation rates and greater rates of early discontinuation and are considered an "at risk" group for nonadherence. For women who hope to have...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2016.12.002
更新日期：2017-06-01 00:00:00
abstract：INTRODUCTION:For patients who have an ipsilateral breast cancer recurrence following prior breast-conserving surgery and radiation, total mastectomy generally is recommended. However, little is known about the suitability and outcomes of nipple-sparing mastectomy (NSM) with immediate breast reconstruction for the treat...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2016.10.011
更新日期：2017-07-01 00:00:00
abstract：:Overexpression of the p185/HER2 protein is seen in 20%-25% of primary breast cancers and is associated with poor prognosis. Recent phase II and III clinical trials demonstrate that trastuzumab is active against breast tumors, both as a single agent and in combination with chemotherapy. In patients with HER2-overexpres...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.3816/cbc.2001.s.003
更新日期：2001-10-01 00:00:00
abstract：BACKGROUND:The adoption of hypofractionated radiotherapy (HFRT) into clinical practice varies widely despite randomized trials and guidelines supporting its equivalence to conventional fractionated radiotherapy (CFRT) for certain patient populations. We assessed the use of HFRT at a single institution from 2011 to 2018...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2020.03.006
更新日期：2020-10-01 00:00:00
abstract：INTRODUCTION:Axillary lymph node dissection (ALND) is currently the recommended procedure in patients with tumor-positive sentinel lymph node biopsy (SLNB). A significant proportion of patients with positive SLNs will not have any additional metastases in nonsentinel lymph nodes (NSLNs). Predictive nomograms could iden...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2014.02.006
更新日期：2014-08-01 00:00:00
abstract：PURPOSE:To evaluate, in a series of early breast cancer (BC) patients treated with hypofractionated adjuvant radiotherapy (RT), whether N-terminal-pro hormone B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin I assay measurements can predict acute clinical or preclinical cardiotoxicity. PATI...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2020.09.005
更新日期：2020-09-10 00:00:00
abstract：BACKGROUND:Medical isotopes are required for sentinel node lymphoscintigraphy in breast cancer, but are in critical shortage. Our center uses a modification of the standard SC, called CRC, that has been shown to require less medical isotope for the same procedure. Our objective was to determine if there was a significa...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2014.07.006
更新日期：2015-02-01 00:00:00
abstract：:Primary squamous cell carcinoma (SCC) of the breast is an extremely rare tumor. It is diagnosed when the malignant cells are entirely of squamous type, the tumor is independent from overlying skin, and other primary SCC sites are excluded. This report presents clinical, radiologic, and histologic correlative findings ...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.3816/CBC.2005.n.030
更新日期：2005-08-01 00:00:00
abstract：:Breast cancer is one of the most frequently diagnosed malignancy among adolescent and young adult (AYA) women, accounting for approximately 14% of all AYA cancer diagnoses and 7% of all breast cancer. Breast cancer in AYA women is believed to represent a more biologically aggressive disease, but aside from commonly kn...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.1016/j.clbc.2014.06.002
更新日期：2014-12-01 00:00:00
abstract：:Tamoxifen reduced the risk of invasive breast cancer by 49% among women at increased risk for breast cancer in the Breast Cancer Prevention Trial P-1, and raloxifene reduced breast cancer incidence by more than 70% in the Multiple Outcomes of Raloxifene Evaluation osteoporosis trial. These findings led the National Su...
journal_title：Clinical breast cancer
pub_type： 临床试验,杂志文章,随机对照试验
doi：10.3816/CBC.2002.n.020
更新日期：2002-06-01 00:00:00
abstract：AIM:Our study was to investigate the heterogeneity of estrogen receptor (ER) expression among tumor sites by using fluorine-18 ((18)F) fluoroestradiol (FES) positron-emission tomography-computed tomography (PET-CT) imaging. METHODS:Thirty-two breast cancer patients underwent both (18)F-FES and (18)F fluorodeoxyglucose...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2013.02.012
更新日期：2013-10-01 00:00:00
abstract：BACKGROUND:Spontaneous rib fractures (SRFs) are defined as fractures without apparent blunt force trauma. This study evaluated the incidence and risk factors of SRFs after treatment of patients with breast cancer based on bone scans. In addition, we analyzed radiation-associated SRFs and identified radiotherapy (RT) fa...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2020.07.009
更新日期：2020-07-23 00:00:00
